Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Success Against COVID-19 Variants, Novavax Will File Vaccine First In UK

Efficacy Lower Against South Africa Strain

Executive Summary

High efficacy in initial readout is good news for global vaccination, and UK will see first emergency use filing.

You may also be interested in...



Coronavirus Update: Pfizer Pledges To Double US Vaccine Output

A round-up of the latest developments, including Celltrion’s new antibody cocktail and SK Biosience and Novavax expanding their collaboration.

H1 Approvals Seen For Russian, Novavax COVID-19 Vaccines In India

Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.

Coronavirus Notebook: EU Publishes AstraZeneca Vaccine Contract, Implements Export Authorization Scheme

The AZ vaccine gets the regulatory go-ahead for use in the EU and the European Medicines Agency says an analysis of data on Pfizer/BioNTech’s Comirnaty has shown no new safety concerns.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel